15/06/2020 - Covid-19
The MARBiobanc of the PSMAR has so far collected more than 2000 samples from 623 COVID-19 patients. In addition, it has follow-up samples -obtained at different times of the clinical evolution of the disease- from 40% of the cases. These samples are difficult to obtain and provide new opportunities for research projects linked to patient evolution (prognosis, biomarkers of evolution, sequelae, etc.). It should be noted that all the samples were collected in strict compliance with the ethical and legal standards set out in the Biomedical Research Act. MARBiobanc pioneered the systematic collection of COVID-19 samples, starting on April 1, thanks to its close coordination with the clinical services at Hospital del Mar and its collaboration with the Catalan Reference Laboratory, which is a node integrated into MARBiobanc.
15/06/2020 - Covid-19
10/06/2020 - Covid-19
On June 8, the Hospital del Mar Medical Research Institute (IMIM) received a very special donation from the P5 infants' class at La Maquinista School, to help in the fight against COVID-19. For 9 years, the children of the La Maquinista School, from class P4 infants upwards, have dedicated the last term of the school year to setting up a company based on the Catalan cooperative model. It is the students themselves, in collaboration with the teaching team, who become partners in the cooperative, define the objectives of the company, set it up, design the products, manufacture them and sell them at a Solidarity Trade Fair organised by the school. This whole process is carried out in a democratic way and decisions are taken in assemblies. This year, despite the situation we are experiencing, they have managed to develop their project in online sessions with the teachers, working from home. They set up a company dedicated to manufacturing toys and origami, called JOCLÀNDIA.
Més informació "The boys and girls of La Maquinista School help in the fight against COVID-19"
10/06/2020 - General information
The Director of the Addictions Process Group within the Institute of Neuropsychiatry and Addictions at the Hospital del Mar (INAD) and a researcher at the Hospital del Mar Medical Research Institute (IMIM) has participated in the drafting of this document, which analyses the different treatments and establishes the standards of use for the entire world. The guide was presented in March at the 63rd session of the Commission on Narcotic Drugs 2020, held at the United Nations Office in Vienna. In March, the United Nations, through its Office on Drugs and Crime (UNODC), and the World Health Organisation (WHO), jointly approved the first International standards for the treatment of drug use disorders. This document was written with the assistance of leading experts in this field, including Dr. Marta Torrens, Director of the Addictions Process Group at INAD and coordinator of the Addictions Research Group at the Hospital del Mar Medical Research Institute (IMIM). Dr. Torrens is the only author from Spain.
05/06/2020 - Press release
Detecting the best research talents and providing these people with financial, structural and stability means advancing in cancer care via translational research projects that improve treatment and diagnosis through innovation with clinical application. This is the ambitious goal of the innovative and cutting-edge I CRIS Research Programmes promoted by CRIS against cancer, which have already received their first awards thanks to a meticulous evaluation and selection process led by a prestigious committee of international experts. Over the next five years, the three winning projects will focus on colorectal cancer (the second-ranked cancer in terms of deaths) prostate cancer (diagnosed in 1.3 million people each year), and immunotherapy, a highly innovative type of treatment that is changing the outlook of many cancers. "Research is our life and only through research are we going to find a cure for cancer. With the CRIS Research Programmes we want to detect the best research talent and provide these people with financial and work-related peace of mind. We want to discover and support the Nobel Prize winners of tomorrow and these first CRIS Programmes are just the beginning. In the next edition we will double the number of winners, underlining our commitment to research in spite of the current situation we are experiencing",explains Diego Megía, president of CRIS against cancer.
Més informació "Dr. Clara Montagut, awarded a I CRIS Programme of Excellence in Cancer Research"
28/05/2020 - Covid-19
The impacts of the COVID-19 pandemic are far reaching and long lasting for people working in Small and Medium Enterprises (SMEs) in terms of people's wellbeing and mental health and the social and economic impacts. he EU-funded large-scale Mental Health Promotion and Intervention in Occupational Settings project began in January 2020. The project aims to improve mental health and wellbeing in the workplace by developing, implementing and evaluating a multilevel intervention targeting both prevalent psychiatric disorders (depression, anxiety disorders) and non-clinical aspects of mental health (stress, burnout, wellbeing, depressive symptoms).
27/05/2020 - General information
The Spanish Transplant Society has awarded the SET 2020 grant to intensify the research activity of Dr. María José Pérez Sáez, a consultant in the Nephrology Service and a researcher at the Hospital del Mar Medical Research Institute (IMIM). It is the only grant of this type that the organisation will award this year. The 30,000 euro grant will enable Dr. Pérez Sáez to work on one of the research projects currently underway in the department and IMIM, looking at fragility in the kidney transplant waiting list. The study of fragility in candidates for kidney transplants was launched by the Hospital del Mar's Nephrology Service in 2016, and currently has data from more than 500 patients. After an initial observational phase, in which the data collected will be analysed prospectively, two more phases have been designed: to biochemically characterise the fragile patient's phenotype, for which a biobank of samples has been set up; and a final intervention phase, with a pre-habilitation clinical trial in these patients while they are awaiting a transplant.
Més informació "Grant from the Spanish Transplant Society for a study by the Nephrology Service"
25/05/2020 - Press release
The company Chemotargets -based in the Barcelona Science Park and a global leader in the development of computational platforms for the design, optimization and safety evaluation of drugs- has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) in order to accelerate research projects for the discovery and development of new oncological therapies that respond to important unmet medical needs. This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between the IMIM experience in the identification of new therapeutic targets in emerging fields of cancer biology and the Chemotargets expertise in drug discovery and development. This initiative will include the use of cutting-edge computational technologies developed specifically to rapidly design drug candidates acting on new mechanisms of action or directed to targets that are difficult to address and for which no identified drugs currently exist.
20/05/2019 - Covid-19
The nationwide MIND/COVID study, headed up by researchers from the Hospital del Mar Medical Research Institute (IMIM) and Hospital del Mar, is one of the few projects funded so far by the Carlos III Health Institute (ISCIII) of the Ministry of Science and Technology. The aim is to study the mental health of healthcare workers and other key groups, as well as COVID-19 patients and a sample of the general Spanish population. Natural disasters such as severe hurricanes, floods or earthquakes, and major epidemic outbreaks -such as SARS, MERS or Ebola- lead to an increase in acute stress, symptoms of anxiety and depression, and other mental health problems. This impact can affect the most vulnerable populations in particular, and lead to the emergence of mental disorders and addictions. Healthcare workers are a vulnerable population because of the risk of contagion and the enormous workload involved in trying to manage the disease.
18/05/2020 - Covid-19
The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET (version 7.0, May 8, 2020), which contains more than 1 million associations between 21,000 genes and 30,000 diseases, and 350,000 associations involving more than 190,000 genomic variants. All the data sources have been updated including the information automatically extracted by text mining of the literature. In addition, a new resource focused on COVID-19 has also been created. DisGeNET is a public knowledge management platform that offers information on genes and genomic variants associated with human diseases, which is obtained by integrating data from more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available and is a resource for sharing and exchanging information recommended by the ELIXIR project, which is called, ELIXIR Recommended Interoperability Resource.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
